A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders
CJ McDougle, JP Holmes, DC Carlson… - Archives of general …, 1998 - jamanetwork.com
Background Neurobiological research has implicated the dopamine and serotonin systems
in the pathogenesis of autism. Open-label reports suggest that the serotonin 2A–dopamine
D 2 antagonist risperidone may be safe and effective in reducing the interfering symptoms of
patients with autism. Methods Thirty-one adults (age [mean+ SD], 28.1±7.3 years) with
autistic disorder (n= 17) or pervasive developmental disorder not otherwise specified (n= 14)
participated in a 12-week double-blind, placebo-controlled trial of risperidone. Patients …
in the pathogenesis of autism. Open-label reports suggest that the serotonin 2A–dopamine
D 2 antagonist risperidone may be safe and effective in reducing the interfering symptoms of
patients with autism. Methods Thirty-one adults (age [mean+ SD], 28.1±7.3 years) with
autistic disorder (n= 17) or pervasive developmental disorder not otherwise specified (n= 14)
participated in a 12-week double-blind, placebo-controlled trial of risperidone. Patients …